Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part V)

As therapies grow more complex, manufacturers must build commercial-scale thinking into early development, focus on meaningful monitoring and favour simplicity to keep production predictable

You need to be a subscriber to read this article.
Click here to find out more.

Britton Jimenez (BJ), SVP, Sales and Marketing at Codexis, tells Dr Kevin Robinson (KSR) that early process understanding, meaningful monitoring and simpler technologies are key to keeping complex therapies predictable and consistent at scale.

Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part V)

KSR: As medicines and manufacturing processes become more complex, what are the biggest challenges when moving from development into scalable production?

BJ: Pharmaceutical innovation is pushing manufacturing into increasingly complex territory. More sophisticated small molecules, advanced biologics and nucleic acid therapeutics are creating possibilities that would have been difficult to imagine a decade ago.

But one message coming through clearly from CPHI Milan 2026 is that scientific complexity cannot simply be passed downstream as a manufacturing issue.

Formulation, scale-up, quality and supply increasingly need to be considered together rather than as separate activities. 

The scale-up challenge is increasingly one of process understanding. Methods that perform successfully during development do not always behave predictably as they move into larger equipment, different facilities or commercial production. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like